B
Bull
Bull · 25%SCLX
$7.07
Precio del escenario
$5.430
-0.136 (-2.51%)Al cierre
Loading chart…
- High
- 5.850
- Open
- 5.570
- VWAP
- 5.56
- Vol
- 46.73K
- Mkt Cap
- 216.81M
- Low
- 5.400
- Amount
- 259.85K
- EV/EBITDA, TTM
- -0.19
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
AI analysis of Scilex Holding Co (SCLX)
sellScilex Holding Co is not a good buy right now due to a very low RSI of 15.718, indicating oversold conditions, and a significant year-to-date change of -58.52%. The company is facing substantial financial losses, with a net income of -114729000 USD in Q2 2026, which raises concerns about its financial health and sustainability.
Métricas de valoración
The current forward P/E ratio for Scilex Holding Co (SCLX) is 2.66, compared to its 5-year average forward P/E of -3.49.
Alphio AI Price Scenarios for SCLX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
8.507-07GlobenewswireSemnur Pharmaceuticals Signs $100 Million Investment Agreement with iHolding
8.507-06NewsfilterScilex Launches Dream Bowl Token Trading on Biconomy Exchange
- 8.507-06Newsfilter
Scilex Secures $100 Million Investment from iHolding Group
8.506-25PRnewswireOramed Pharmaceuticals Joins Russell Indexes, Strengthens Financial Position
8.506-11NASDAQ.COMBiotech Companies See Significant Stock Gains
SCLX FAQ — answered by Alphio AI
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Scilex Holding Co is not a good buy right now due to a very low RSI of 15.718, indicating oversold conditions, and a significant year-to-date change of -58.52%. The company is facing substantial financial losses, with a net income of -114729000 USD in Q2 2026, which raises concerns about its financial health and sustainability.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.